Genentech reported higher-than-expected quarterly sales of its most important product, the cancer drug Avastin, and raised its earnings outlook for the year.
... Avastin alone to treat a subgroup of recurrent Grade 3 brain tumors showed it was safe ... annually in the U.S. Most are under age 50.
Avastin, known generically as bevacizumab, is the first approved ...
The use of Avastin alone to treat a subgroup of recurrent Grade 3 brain tumors showed it was safe and effective at delaying tumor progression, according to a retrospective study of 22 patients.
SAN FRANCISCO, April 22 (UPI) -- The drug Avastin fell short in a clinical trial of its goal to reduce the recurrence of early-stage colon cancer, U.S. drug maker Genentech says.
WASHINGTON, May 11 (UPI) -- The U.S. Food and Drug Administration has approved Avastin (bevacizumab) to treat patients with glioblastoma multiforme -- a form of brain cancer.
... be validated in patients with newly diagnosed glioblastomas.
A significant study finding was that Avastin was nearly as effective alone as it was when given with chemotherapy, but was much better ...
... opened -- a window of time lasting approximately five minutes -- the chemotherapeutic agent Avastin is injected directly into the malignant tumor.
Participants in the trial will be given varying ...
The Nova Scotia government says it will pay for an expensive colorectal cancer drug that it has previously refused to cover.
... ."
Approaches using molecules that neutralize growth factors have proven themselves in other cases. The Avastin antibody works well to block the molecule that activates the vascular endothelial ...
... neurotoxicity and greatly enhanced oral availability. While a number of angiogenesis inhibitors, such as Avastin, are now commercially available, most target only single angiogenic factors, such as ...
Avastin, which can cost as much as $100,000 a year, has become one of the most popular cancer drugs, but studies show it prolongs life by only a few months.
The Nova Scotia government has started paying for a costly drug used in the treatment of advanced colorectal cancer.
... Reuters) - GlaxoSmithKline Plc's head of biotech research is excited about a new generation of "slimline" antibody medicines that may be successors to current blockbusters such as Avastin and Rituxan.
... of compounds that have already been approved for treating patients: the anti-cancer drug bevacizumab (Avastin) and Copper-64, a radioactive copper nuclide, which is approved by the US Food and Drug ...
... will require repeated dosages of anti-VEGF agents."
The study is also relevant to the drug Avastin, which was initially approved for intravenous use as an anti-angiogenic agent in the treatment of ...
